サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1542489

心血管治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測

Global Cardiovascular Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

出版日
ページ情報
英文 162 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
心血管治療薬の世界市場調査レポート：産業分析、規模、シェア、成長、動向、2024年から2032年までの予測
出版日: 2024年07月01日
発行: Value Market Research
ページ情報: 英文 162 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

心血管治療薬市場の世界需要は、2023年の1,835億4,000万米ドルから2032年には2,685億5,000万米ドル近くの市場規模に達すると推定され、調査期間2024～2032年のCAGRは4.32%です。

心血管治療薬は、心臓や血管に関連する疾患や症状の治療・管理に使用される医薬品です。これらの薬剤には、抗高血圧薬、スタチン、抗凝固薬、抗不整脈薬などが含まれます。これらは高血圧、冠動脈疾患、心不全、不整脈などの状態を管理するために処方されます。これらの薬剤は、血圧の低下、コレステロール値の低下、血栓形成の防止、心臓リズムの安定化など、さまざまなメカニズムで作用します。

市場力学

心血管治療薬市場は、世界的に心血管疾患の有病率が高く、効果的な医薬品による介入が必要であることが市場を牽引しています。医薬品開発の進歩と研究・技術革新への投資の増加は、より効果的な新しい治療法の提供に寄与しています。特定の心血管系疾患を持つ患者の予後を改善する個別化医療や標的療法の開発にはビジネスチャンスがあります。さらに、高齢化人口の増加と心臓の健康に対する意識の高まりが、心血管治療薬の需要を促進しています。新興市場におけるヘルスケアインフラの拡大と医療へのアクセスの向上は、市場の成長をさらに後押しします。予防医療と慢性疾患管理への注力も、心血管治療薬の提供拡大の機会を生み出しています。しかし、厳しい規制要件と高い研究開発費が、心血管治療薬市場の成長を抑制する可能性があります。

調査レポートは、ポーターのファイブフォースモデル、市場の魅力分析、バリューチェーン分析をカバーしています。これらのツールは、業界の構造を明確に把握し、世界レベルでの競合の魅力を評価するのに役立ちます。さらに、これらのツールは、心血管治療薬の世界市場における各セグメントを包括的に評価することもできます。心血管治療薬業界の成長と動向は、この調査に全体的なアプローチを提供します。

市場セグメンテーション

心血管治療薬市場レポートのこのセクションでは、国別および地域別のセグメントに関する詳細なデータを提供し、戦略担当者が今後のビジネスチャンスとともに、それぞれの製品やサービスのターゲット層を特定するのに役立ちます。

薬剤クラス別

  • レニン-アンジオテンシン系遮断薬（ACE阻害薬およびアンジオテンシン受容体遮断薬）
  • ベータ遮断薬
  • 利尿薬
  • 抗血液凝固薬（抗凝固薬および血小板凝集阻害薬）
  • 抗高脂血症薬
  • その他の降圧薬
  • カルシウム拮抗薬
  • その他

適応症別

  • 高血圧症
  • 高脂血症
  • 冠動脈疾患
  • 末梢動脈疾患
  • 不整脈
  • その他

流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

地域分析

本セクションでは、北米、欧州、アジア太平洋、ラテンアメリカ、中東・アフリカにおける心血管治療薬市場の現在および将来の需要を明らかにする地域展望を取り上げます。さらに、すべての主要地域における各用途セグメントの需要、推定・予測にも焦点を当てています。

カスタム要件がある場合は、お問い合わせください。当社の調査チームは、お客様のニーズに応じてカスタマイズしたレポートを提供することができます。

目次

第1章 序文

第2章 エグゼクティブサマリー

  • 市場のハイライト
  • 世界市場スナップショット

第3章 心血管治療薬- 業界分析

  • イントロダクション：市場力学
  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 業界動向
  • ポーターのファイブフォース分析
  • 市場の魅力分析

第4章 バリューチェーン分析

  • バリューチェーン分析
  • 原材料分析
    • 原材料リスト
    • 原材料メーカーリスト
    • 主要原材料の価格動向
  • 潜在的バイヤーのリスト
  • マーケティングチャネル
    • ダイレクトマーケティング
    • インダイレクトマーケティング
    • マーケティングチャネル発展動向

第5章 心血管治療薬の世界市場分析：薬剤クラス別

  • 薬剤クラス別の概要
  • 薬剤クラス別過去および予測データ分析
  • レニン-アンジオテンシン系遮断薬（ACE阻害薬およびアンジオテンシン受容体遮断薬）
  • β遮断薬
  • 利尿薬
  • 抗血液凝固薬（抗凝固薬、血小板凝集阻害薬）
  • 抗高脂血症薬
  • その他の降圧薬
  • カルシウム拮抗薬
  • その他

第6章 心血管治療薬の世界市場分析：適応症別

  • 適応症別の概要
  • 適応症別の過去および予測データ分析
  • 高血圧症
  • 高脂血症
  • 冠動脈疾患
  • 末梢動脈疾患
  • 不整脈
  • その他

第7章 心血管治療薬の世界市場分析：流通チャネル別

  • 流通チャネル別概要
  • 流通チャネル別過去および予測データ分析
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第8章 心血管治療薬の世界市場分析：地域別

  • 地域別展望
  • イントロダクション
  • 北米売上分析
    • 概要、実績と予測
    • 北米：セグメント別
    • 北米国別
    • 米国
    • カナダ
    • メキシコ
  • 欧州売上分析
    • 概要、実績と予測
    • 欧州セグメント別
    • 欧州国別
    • 英国
    • フランス
    • ドイツ
    • イタリア
    • ロシア
    • その他欧州
  • アジア太平洋売上分析
    • 概要、実績と予測
    • アジア太平洋セグメント別
    • アジア太平洋国別
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア
    • 東南アジア
    • その他アジア太平洋
  • ラテンアメリカ売上分析
    • 概要、実績と予測
    • ラテンアメリカセグメント別
    • ラテンアメリカ国別
    • ブラジル
    • アルゼンチン
    • ペルー
    • チリ
    • その他ラテンアメリカ
  • 中東・アフリカ売上分析
    • 概要、実績と予測
    • 中東・アフリカセグメント別
    • 中東・アフリカ国別一覧
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • 南アフリカ
    • その他中東とアフリカ

第9章 心血管治療薬企業の競合情勢

  • 心血管治療薬の市場競合
  • パートナーシップ/提携/合意
  • 合併・買収
  • 新製品の上市
  • その他の開発

第10章 企業プロファイル

  • 上位企業の市場シェア分析
  • 市場集中度
  • AstraZeneca
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co. Inc.
  • Bristol-Myers Squibb Company
  • Bayer AG
  • Sanofi
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Gilead Sciences Inc.
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Eli Lilly And Company
  • Otsuka Holdings Co Ltd.
  • Takeda Pharmaceuticals Company Ltd
図表

LIST OF TABLES

  • Market Snapshot
  • Drivers: Impact Analysis
  • Restraints: Impact Analysis
  • List of Raw Material
  • List of Raw Material Manufactures
  • Analysis By Drug Class (USD MN)
  • Renin-Angiotensin System Blockers (ACE Inhibitors and Angiotensin Receptor Blockers) Market Sales By Geography (USD MN)
  • Beta Blockers Market Sales By Geography (USD MN)
  • Diuretics Market Sales By Geography (USD MN)
  • Anti-Clotting Agents (Anti-Coagulants and Platelet Aggregation Inhibitors) Market Sales By Geography (USD MN)
  • Antihyperlipidemics Market Sales By Geography (USD MN)
  • Other Antihypertensive Market Sales By Geography (USD MN)
  • Calcium Channel Blockers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Indication (USD MN)
  • Hypertension Market Sales By Geography (USD MN)
  • Hyperlipidemia Market Sales By Geography (USD MN)
  • Coronary Artery Disease Market Sales By Geography (USD MN)
  • Peripheral Artery Disease Market Sales By Geography (USD MN)
  • Arrhythmia Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Cardiovascular Drugs Market Sales By Geography (USD MN)
  • North America Market Analysis (USD MN)
  • United States Market Analysis (USD MN)
  • Canada Market Analysis (USD MN)
  • Mexico Market Analysis (USD MN)
  • Europe Market Analysis (USD MN)
  • Europe Market Estimate By Country (USD MN)
  • United Kingdom Market Analysis (USD MN)
  • France Market Analysis (USD MN)
  • Germany Market Analysis (USD MN)
  • Italy Market Analysis (USD MN)
  • Russia Market Analysis (USD MN)
  • Spain Market Analysis (USD MN)
  • Rest of Europe Market Analysis (USD MN)
  • Asia Pacific Market Analysis (USD MN)
  • China Market Analysis (USD MN)
  • Japan Market Analysis (USD MN)
  • India Market Analysis (USD MN)
  • South Korea Market Analysis (USD MN)
  • Australia Market Analysis (USD MN)
  • South East Asia Market Analysis (USD MN)
  • Rest of Asia Pacific Market Analysis (USD MN)
  • Latin America Market Analysis (USD MN)
  • Brazil Market Analysis (USD MN)
  • Argentina Market Analysis (USD MN)
  • Peru Market Analysis (USD MN)
  • Chile Market Analysis (USD MN)
  • Rest of Latin America Market Analysis (USD MN)
  • Middle East & Africa Market Analysis (USD MN)
  • Saudi Arabia Market Analysis (USD MN)
  • UAE Market Analysis (USD MN)
  • Israel Market Analysis (USD MN)
  • South Africa Market Analysis (USD MN)
  • Rest of Middle East and Africa Market Analysis (USD MN)
  • Partnership/Collaboration/Agreement
  • Mergers And Acquisition

LIST OF FIGURES

  • Research Scope of Cardiovascular Drugs Report
  • Market Research Process
  • Market Research Methodology
  • Global Cardiovascular Drugs Market Size, By Region (USD MN)
  • Porters Five Forces Analysis
  • Market Attractiveness Analysis By Drug Class
  • Market Attractiveness Analysis By Indication
  • Market Attractiveness Analysis By Distribution Channel
  • Market Attractiveness Analysis By Region
  • Value Chain Analysis
  • Global Market Analysis By Drug Class (USD MN)
  • Renin-Angiotensin System Blockers (ACE Inhibitors and Angiotensin Receptor Blockers) Market Sales By Geography (USD MN)
  • Beta Blockers Market Sales By Geography (USD MN)
  • Diuretics Market Sales By Geography (USD MN)
  • Anti-Clotting Agents (Anti-Coagulants and Platelet Aggregation Inhibitors) Market Sales By Geography (USD MN)
  • Antihyperlipidemics Market Sales By Geography (USD MN)
  • Other Antihypertensive Market Sales By Geography (USD MN)
  • Calcium Channel Blockers Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Indication (USD MN)
  • Hypertension Market Sales By Geography (USD MN)
  • Hyperlipidemia Market Sales By Geography (USD MN)
  • Coronary Artery Disease Market Sales By Geography (USD MN)
  • Peripheral Artery Disease Market Sales By Geography (USD MN)
  • Arrhythmia Market Sales By Geography (USD MN)
  • Others Market Sales By Geography (USD MN)
  • Global Market Analysis By Distribution Channel (USD MN)
  • Hospital Pharmacy Market Sales By Geography (USD MN)
  • Retail Pharmacy Market Sales By Geography (USD MN)
  • Online Pharmacy Market Sales By Geography (USD MN)
  • Global Market Sales (USD MN)
  • North America Market Sales (USD MN)
  • Europe Market Sales (USD MN)
  • Asia Pacific Market Sales (USD MN)
  • Latin America Market Sales (USD MN)
  • Middle East & Africa Market Sales (USD MN)
  • Recent Development in Industry
  • Top Company Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.

目次
Product Code: VMR11212079

The global demand for Cardiovascular Drugs Market is presumed to reach the market size of nearly USD 268.55 Billion by 2032 from USD 183.54 Billion in 2023 with a CAGR of 4.32% under the study period 2024-2032.

Cardiovascular drugs are medications used to treat and manage diseases and conditions related to the heart and blood vessels. These drugs include antihypertensives, statins, anticoagulants, and antiarrhythmics, among others. They are prescribed to manage conditions such as hypertension, coronary artery disease, heart failure, and arrhythmias. These drugs work by various mechanisms, including reducing blood pressure, lowering cholesterol levels, preventing blood clot formation, and stabilizing heart rhythms.

MARKET DYNAMICS

The cardiovascular drugs market is driven by the high prevalence of cardiovascular diseases globally, which necessitates effective pharmaceutical interventions. Advances in drug development and increasing investments in research and innovation contribute to the availability of new and more effective treatments. Opportunities lie in the development of personalized medicine and targeted therapies that offer improved outcomes for patients with specific cardiovascular conditions. Additionally, the growing aging population and rising awareness about heart health drive the demand for cardiovascular drugs. Expanding healthcare infrastructure and increased access to medical care in emerging markets further support market growth. Focusing on preventive care & chronic disease management also creates opportunities for expanding cardiovascular drug offerings. However, stringent regulatory requirements and high R&D costs may restrain the growth of the cardiovascular drugs market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of Cardiovascular Drugs. The growth and trends of Cardiovascular Drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the Cardiovascular Drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

  • Renin-Angiotensin System Blockers (ACE Inhibitors and Angiotensin Receptor Blockers)
  • Beta Blockers
  • Diuretics
  • Anti-Clotting Agents (Anti-Coagulants and Platelet Aggregation Inhibitors)
  • Antihyperlipidemics
  • Other Antihypertensive
  • Calcium Channel Blockers
  • Others

By Indication

  • Hypertension
  • Hyperlipidemia
  • Coronary Artery Disease
  • Peripheral Artery Disease
  • Arrhythmia
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Cardiovascular Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Cardiovascular Drugs market include AstraZeneca, Pfizer Inc., Novartis AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Bayer AG, Sanofi, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Abbott Laboratories, Gilead Sciences Inc., Johnson & Johnson, Astellas Pharma Inc., Eli Lilly And Company, Otsuka Holdings Co Ltd., Takeda Pharmaceuticals Company Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Report Description
    • 1.1.1 Objective
    • 1.1.2 Target Audience
    • 1.1.3 Unique Selling Proposition (USP) & offerings
  • 1.2. Research Scope
  • 1.3. Research Methodology
    • 1.3.1 Market Research Process
    • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Highlights of Market
  • 2.2. Global Market Snapshot

3. CARDIOVASCULAR DRUGS - INDUSTRY ANALYSIS

  • 3.1. Introduction - Market Dynamics
  • 3.2. Market Drivers
  • 3.3. Market Restraints
  • 3.4. Opportunities
  • 3.5. Industry Trends
  • 3.6. Porter's Five Force Analysis
  • 3.7. Market Attractiveness Analysis
    • 3.7.1 Market Attractiveness Analysis By Drug Class
    • 3.7.2 Market Attractiveness Analysis By Indication
    • 3.7.3 Market Attractiveness Analysis By Distribution Channel
    • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

  • 4.1. Value Chain Analysis
  • 4.2. Raw Material Analysis
    • 4.2.1 List of Raw Materials
    • 4.2.2 Raw Material Manufactures List
    • 4.2.3 Price Trend of Key Raw Materials
  • 4.3. List of Potential Buyers
  • 4.4. Marketing Channel
    • 4.4.1 Direct Marketing
    • 4.4.2 Indirect Marketing
    • 4.4.3 Marketing Channel Development Trend

5. GLOBAL CARDIOVASCULAR DRUGS MARKET ANALYSIS BY DRUG CLASS

  • 5.1. Overview By Drug Class
  • 5.2. Historical and Forecast Data Analysis By Drug Class
  • 5.3. Renin-Angiotensin System Blockers (ACE Inhibitors and Angiotensin Receptor Blockers) Historic and Forecast Sales By Regions
  • 5.4. Beta Blockers Historic and Forecast Sales By Regions
  • 5.5. Diuretics Historic and Forecast Sales By Regions
  • 5.6. Anti-Clotting Agents (Anti-Coagulants and Platelet Aggregation Inhibitors) Historic and Forecast Sales By Regions
  • 5.7. Antihyperlipidemics Historic and Forecast Sales By Regions
  • 5.8. Other Antihypertensive Historic and Forecast Sales By Regions
  • 5.9. Calcium Channel Blockers Historic and Forecast Sales By Regions
  • 5.10. Others Historic and Forecast Sales By Regions

6. GLOBAL CARDIOVASCULAR DRUGS MARKET ANALYSIS BY INDICATION

  • 6.1. Overview By Indication
  • 6.2. Historical and Forecast Data Analysis By Indication
  • 6.3. Hypertension Historic and Forecast Sales By Regions
  • 6.4. Hyperlipidemia Historic and Forecast Sales By Regions
  • 6.5. Coronary Artery Disease Historic and Forecast Sales By Regions
  • 6.6. Peripheral Artery Disease Historic and Forecast Sales By Regions
  • 6.7. Arrhythmia Historic and Forecast Sales By Regions
  • 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL CARDIOVASCULAR DRUGS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

  • 7.1. Overview By Distribution Channel
  • 7.2. Historical and Forecast Data Analysis By Distribution Channel
  • 7.3. Hospital Pharmacy Historic and Forecast Sales By Regions
  • 7.4. Retail Pharmacy Historic and Forecast Sales By Regions
  • 7.5. Online Pharmacy Historic and Forecast Sales By Regions

8. GLOBAL CARDIOVASCULAR DRUGS MARKET ANALYSIS BY GEOGRAPHY

  • 8.1. Regional Outlook
  • 8.2. Introduction
  • 8.3. North America Sales Analysis
    • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.3.2 North America By Segment Sales Analysis
    • 8.3.3 North America By Country Sales Analysis
    • 8.3.4 United States Sales Analysis
    • 8.3.5 Canada Sales Analysis
    • 8.3.6 Mexico Sales Analysis
  • 8.4. Europe Sales Analysis
    • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.4.2 Europe By Segment Sales Analysis
    • 8.4.3 Europe By Country Sales Analysis
    • 8.4.4 United Kingdom Sales Analysis
    • 8.4.5 France Sales Analysis
    • 8.4.6 Germany Sales Analysis
    • 8.4.7 Italy Sales Analysis
    • 8.4.8 Russia Sales Analysis
    • 8.4.9 Rest Of Europe Sales Analysis
  • 8.5. Asia Pacific Sales Analysis
    • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.5.2 Asia Pacific By Segment Sales Analysis
    • 8.5.3 Asia Pacific By Country Sales Analysis
    • 8.5.4 China Sales Analysis
    • 8.5.5 India Sales Analysis
    • 8.5.6 Japan Sales Analysis
    • 8.5.7 South Korea Sales Analysis
    • 8.5.8 Australia Sales Analysis
    • 8.5.9 South East Asia Sales Analysis
    • 8.5.10 Rest Of Asia Pacific Sales Analysis
  • 8.6. Latin America Sales Analysis
    • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.6.2 Latin America By Segment Sales Analysis
    • 8.6.3 Latin America By Country Sales Analysis
    • 8.6.4 Brazil Sales Analysis
    • 8.6.5 Argentina Sales Analysis
    • 8.6.6 Peru Sales Analysis
    • 8.6.7 Chile Sales Analysis
    • 8.6.8 Rest of Latin America Sales Analysis
  • 8.7. Middle East & Africa Sales Analysis
    • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
    • 8.7.2 Middle East & Africa By Segment Sales Analysis
    • 8.7.3 Middle East & Africa By Country Sales Analysis
    • 8.7.4 Saudi Arabia Sales Analysis
    • 8.7.5 UAE Sales Analysis
    • 8.7.6 Israel Sales Analysis
    • 8.7.7 South Africa Sales Analysis
    • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE CARDIOVASCULAR DRUGS COMPANIES

  • 9.1. Cardiovascular Drugs Market Competition
  • 9.2. Partnership/Collaboration/Agreement
  • 9.3. Merger And Acquisitions
  • 9.4. New Product Launch
  • 9.5. Other Developments

10. COMPANY PROFILES OF CARDIOVASCULAR DRUGS INDUSTRY

  • 10.1. Top Companies Market Share Analysis
  • 10.2. Market Concentration Rate
  • 10.3. AstraZeneca
    • 10.3.1 Company Overview
    • 10.3.2 Company Revenue
    • 10.3.3 Products
    • 10.3.4 Recent Developments
  • 10.4. Pfizer Inc.
    • 10.4.1 Company Overview
    • 10.4.2 Company Revenue
    • 10.4.3 Products
    • 10.4.4 Recent Developments
  • 10.5. Novartis AG
    • 10.5.1 Company Overview
    • 10.5.2 Company Revenue
    • 10.5.3 Products
    • 10.5.4 Recent Developments
  • 10.6. Merck & Co. Inc.
    • 10.6.1 Company Overview
    • 10.6.2 Company Revenue
    • 10.6.3 Products
    • 10.6.4 Recent Developments
  • 10.7. Bristol-Myers Squibb Company
    • 10.7.1 Company Overview
    • 10.7.2 Company Revenue
    • 10.7.3 Products
    • 10.7.4 Recent Developments
  • 10.8. Bayer AG
    • 10.8.1 Company Overview
    • 10.8.2 Company Revenue
    • 10.8.3 Products
    • 10.8.4 Recent Developments
  • 10.9. Sanofi
    • 10.9.1 Company Overview
    • 10.9.2 Company Revenue
    • 10.9.3 Products
    • 10.9.4 Recent Developments
  • 10.10. Boehringer Ingelheim GmbH
    • 10.10.1 Company Overview
    • 10.10.2 Company Revenue
    • 10.10.3 Products
    • 10.10.4 Recent Developments
  • 10.11. F. Hoffmann-La Roche Ltd.
    • 10.11.1 Company Overview
    • 10.11.2 Company Revenue
    • 10.11.3 Products
    • 10.11.4 Recent Developments
  • 10.12. Abbott Laboratories
    • 10.12.1 Company Overview
    • 10.12.2 Company Revenue
    • 10.12.3 Products
    • 10.12.4 Recent Developments
  • 10.13. Gilead Sciences Inc.
    • 10.13.1 Company Overview
    • 10.13.2 Company Revenue
    • 10.13.3 Products
    • 10.13.4 Recent Developments
  • 10.14. Johnson & Johnson
    • 10.14.1 Company Overview
    • 10.14.2 Company Revenue
    • 10.14.3 Products
    • 10.14.4 Recent Developments
  • 10.15. Astellas Pharma Inc.
    • 10.15.1 Company Overview
    • 10.15.2 Company Revenue
    • 10.15.3 Products
    • 10.15.4 Recent Developments
  • 10.16. Eli Lilly And Company
    • 10.16.1 Company Overview
    • 10.16.2 Company Revenue
    • 10.16.3 Products
    • 10.16.4 Recent Developments
  • 10.17. Otsuka Holdings Co Ltd.
    • 10.17.1 Company Overview
    • 10.17.2 Company Revenue
    • 10.17.3 Products
    • 10.17.4 Recent Developments
  • 10.18. Takeda Pharmaceuticals Company Ltd
    • 10.18.1 Company Overview
    • 10.18.2 Company Revenue
    • 10.18.3 Products
    • 10.18.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies